However, more recently, the ascending spread of alpha-synuclein through the microbiota-gut-brain-axis has been proposed as a link between GI dysfunction and cognitive decline (51), in addition to varying metabolic pathways of the gut microbiota that affect the efficacy of PD therapies (52). This evidence concerns the gene SNCA and Parkinson disease.